BNTX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

BioNTech SE · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 89.33 USD
-2.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -8.6% below the Trend Line and sits at 22.1% of its 52-week range. The latest completed week returned -2.4%, after a -2.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 35/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 27 out of 100
Latest Close 89.33 USD 24 Jul 2026
1W Return -2.4% latest completed week
4W Return -2.1% short-term follow-through
12W Return -8.4% quarterly tape
Trend Breadth 11.5% 6 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.4% Latest completed week; four-week move -2.1%. Indicator stack 6/48 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 35/100 conviction; expected move 11.1%. News sentiment 53/100 68 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -8.6% below the Trend Line and sits at 22.1% of its 52-week range. The latest completed week returned -2.4%, after a -2.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1712-week average 0.11

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.17Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.1% over four weeks, -8.4% over 12 weeks, and -22.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-2.4%
4W-2.1%
12W-8.4%
26W-23.0%
52W-22.5%
Active trend streak0 weeks
Active weeks in one year6
Trend breadth11.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.27Latest activity-pressure read.
Pressure change38.4%Four-week change in activity pressure.
Leadership-18.32Latest relative-leadership reading.
RS change16.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength12/100Blend of value, momentum, and quality. Underlying universe rank 89; rank 1 is best.
Value36/100Relative valuation strength. Underlying universe rank 65; rank 1 is best.
Quality30/100Profitability and accounting quality. Underlying universe rank 71; rank 1 is best.
Momentum15/100Medium-term price momentum. Underlying universe rank 86; rank 1 is best.
Growth29/100Revenue and earnings growth. Underlying universe rank 72; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
8.1x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
12.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
73.2%
Gross profit retained from each unit of revenue.
Operating margin
-41.7%
Operating profit retained from revenue.
Free-cash-flow margin
56.8%
Free cash flow generated from revenue.
Return on invested capital
-9.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
1.9%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
114.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
13.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

BNTX shows bullish options pressure with a 35/100 conviction score, put-call volume ratio of 0.56, expected move of 11.1%, and Sharemaestro trend signal inactive.

Conviction35/100
Expected move11.1%
Put/call volume0.56
Pressure31
Speculation19
Volatility76
Trend agreement38
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 68 relevant articles.

17 positive · 44 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
Options expected move11.1%Nearest-chain priced movement where available.
52-week drawdown-28.0%Distance below the 52-week high.
13-week volatility4.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+7.8%Week of 17 Apr.
Worst week-10.2%Week of 13 Mar.
Latest week-2.4%Week of 24 Jul.

Shape of recent returns

Strong gains6
Modest gains6
Flat weeks0
Modest losses6
Sharp losses8
Recent vol4.5%13-week weekly-return volatility.
Base vol5.5%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew4.2% / -4.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape25/100

Trend, activity pressure, participation, and risk combine to a 25/100 tape read.

 Indicator analysis12/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.17; No reversal markers Factors22/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 55 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options50/100

BNTX shows bullish options pressure with a 35/100 conviction score, put-call volume ratio of 0.56, expected move of 11.1%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 11.1% Sentiment53/100

Weighted news tone is neutral across 68 relevant articles.

BioNTech stock trades near cash value, signalin... Insiders50/100

No recent insider transaction evidence is stored.

 Earnings2d

Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202689.33 USD-2.4%97.69 USD101.4 USD-0.27-18.323.3MOff
17 Jul 202691.48 USD-0.0%97.86 USD101.5 USD-0.07-18.414.2MOff
10 Jul 202691.49 USD-6.2%97.90 USD101.6 USD-0.08-22.403.7MOff
3 Jul 202697.55 USD6.9%98.01 USD101.7 USD-0.11-16.543.4MOff
26 Jun 202691.22 USD0.4%97.97 USD101.8 USD-0.44-21.854.5MOff
19 Jun 202690.89 USD0.4%98.36 USD101.9 USD-0.54-26.203.5MOff
12 Jun 202690.54 USD2.8%98.52 USD102.0 USD-0.61-25.217.7MOff
5 Jun 202688.08 USD-8.2%98.94 USD102.2 USD-0.74-26.224.6MOff
29 May 202695.95 USD4.1%99.44 USD102.3 USD-0.66-23.954.4MOff
22 May 202692.14 USD2.9%99.70 USD102.4 USD-0.72-25.324.2MOff
15 May 202689.55 USD-4.9%100.2 USD102.4 USD-0.59-27.073.7MOff
8 May 202694.12 USD-3.5%100.7 USD102.6 USD-0.44-24.045.8MOff
1 May 202697.54 USD-7.5%100.9 USD102.6 USD-0.43-17.483.7MOff
24 Apr 2026105.5 USD2.5%101.2 USD102.7 USD-0.48-10.106.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.